+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML)



The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML)



Leukemia Research 38(10): 1184-1190



We retrospectively evaluated the prognostic significance of polypharmacy and inappropriate medication use among 150 patients >60 years of age receiving induction chemotherapy for acute myelogenous leukemia (AML). After adjustment for age and comorbidity, increased number of medications at diagnosis (≥ 4 versus ≤ 1) was associated with increased 30-day mortality (OR=9.98, 95% CI=1.18-84.13), lower odds of complete remission status (OR=0.20, 95% CI=0.06-0.65), and higher overall mortality (HR=2.13, 95% CI=1.15-3.92). Inappropriate medication use (classified according to Beers criteria) was not significantly associated with clinical outcomes. Polypharmacy warrants further study as a modifiable marker of vulnerability among older adults with AML.

(PDF emailed within 0-6 h: $19.90)

Accession: 056446723

Download citation: RISBibTeXText

PMID: 25127690

DOI: 10.1016/j.leukres.2014.06.018


Related references

Older adults with acute myeloid leukemia treated with intensive chemotherapy: "old" prognostic algorithms may not apply. Haematologica 103(11): 1758-1759, 2018

Acute myelogenous leukemia in older adults. Oncologist 14(3): 222-232, 2009

Treatment of acute myelogenous leukemia in older adults. Leukemia 14(3): 480-487, 2000

Loss of DCC gene expression is of prognostic importance in acute myelogenous leukemia. Clinical Cancer Research 8(6): 1882-1888, 2002

Prognostic value of age and bone marrow karyotype in 78 adults with acute myelogenous leukemia. Cancer Genetics & Cytogenetics 7(2): 153-164, 1982

Importance of prognostic stratification via gene mutation analysis in elderly patients with acute myelogenous leukemia. International Journal of Laboratory Hematology 2019, 2019

Eastern cooperative onocology group studies in the treatment of older adults with acute myelogenous leukemia. Annals of Hematology 78(SUPPL 2): S18, 1999

Adult acute myelogenous leukemia: Prognostic factors, induction remission treatment and importance of postremission chemotherapy. Acta Haematologica Polonica 30(1): 37-52, 1999

CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine. Leukemia and Lymphoma 59(4): 821-828, 2017

The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. Journal of the American Geriatrics Society 59(10): 1837-1846, 2012

Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood 121(21): 4287-4294, 2013

Prognosis of patients with acute myelogenous leukemia preceded by a preleukemia syndrome compared to patients with de novo acute myelogenous leukemia when treated with intensive chemotherapy. Experimental Hematology 16(6): 476, 1988

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer 124(12): 2534-2540, 2018

Prognostic factors affecting response and survival in adults with acute lymphocytic leukemia treated on cancer and leukemia group b 8011. Proceedings American Society of Clinical Oncology Annual Meeting 5: 156, 1986

Diagnostic and prognostic importance of immunophenotyping in adults with acute myeloid leukemia. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres Dans les Recherches sur le Cancer 131: 369-379, 1993